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Abstract
Background: Lung cancer is the leading cause of cancer mortality worldwide. Early diagnosis and treatment is a
key factor in reducing mortality and improving patient outcomes. To achieve this, it is important to understand the
diagnostic pathways of cancer patients. Patients from Culturally and Linguistically Diverse (CALD) are a vulnerable
group for lung cancer with higher mortality rates than Caucasian patients. The aim of this study is to explore
differences in the lung cancer diagnostic pathways between CALD and Anglo-Australian patients and factors
underlying these differences.
Methods: This is a prospective, observational cohort study using a mixed-method approach. Quantitative data
regarding time intervals in the lung cancer diagnostic pathways will be gathered via patient surveys, General
practitioner (GP) review of general practice records, and case-note analysis of hospital records. Qualitative data will
be gathered via structured interviews with lung cancer patients, GPs, and hospital specialists. The study will be
conducted in five study sites across three states in Australia. Anglo-Australian patients and patients from five CALD
groups (i.e., Arabic, Chinese, Greek, Italian and Vietnamese communities) will mainly be identified through the list of
new cases presented at lung multidisciplinary team meetings. For the quantitative component, it is anticipated that
724 patients (362 Anglo-Australian and 362 CALD patients) will be recruited to obtain a final sample of 290 (145 per
group) assuming a 50% patient survey completion rate and a 80% GP record review completion rate. For the
qualitative component, 60 interviews with lung cancer patients (10 Anglo-Australian and 10 patients per CALD
group), 20 interviews with GPs, and 20 interviews with specialists will be conducted.
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Discussion: This is the first Australian study to compare the time intervals along the lung cancer diagnostic pathway
between CALD and Anglo-Australian patients. The study will also explore the underlying patient, healthcare provider,
and health system factors that influence the time intervals in the two groups. This information will improve our
understanding of the effect of ethnicity on health outcomes among lung cancer patients and will inform future
interventions aimed at early diagnosis and treatment for lung cancer, particularly patients from CALD backgrounds.
Trial registration: The project was retrospectively registered with Australian New Zealand Clinical Trials Registry
(registration number: ACTRN12617000957392, date registered: 4th July 2017).
Keywords: Lung cancer, Ethnicity, Time intervals, Cancer diagnostic pathway
Background
Lung cancer is the most common cancer worldwide. In
2012, it was estimated that there were 1.8 million new cases
of lung cancer, accounting for 13% of all incident cancer
cases [1]. Lung cancer is also the leading cause of cancer
mortality, estimated to be responsible for 1.59 million (or
19.4% of the total) cancer deaths in 2012 [1]. One reason for
this high mortality rate is that lung cancer is often diagnosed
at a late stage, which is associated with higher mortality than
early-stage disease [2–5]. Walters et al. (2013) analysed
population-based data of lung cancer between 2004 and
2007 in six developed countries (including Australia, Canada,
Denmark, Norway, Sweden and the UK) and found that at
least half of lung cancer patients were diagnosed at a late
stage when curative treatment is unlikely as an option.
Early diagnosis and treatment is considered a key factor in
reducing lung cancer mortality and improving patient out-
comes [6]. When cancer patients are diagnosed early, they
are more likely to be suitable for curative treatment, leading
to a greater probability of survival, less morbidity, and im-
proved quality of life [7]. To achieve early diagnosis and
treatment, it is important to understand the diagnostic and
treatment pathways of cancer patients in order to inform
the development of interventions to reduce diagnostic and
treatment delay [6, 8]. Guided by the Model of Pathways to
Treatment [8], the LEAD project (Lung cancer diagnostic
and treatment pathways: a comparison between Culturally
and linguistically diverse [CALD] and Anglo-Australian pa-
tients) will use a mixed-method, observational cohort design
to explore the pathways to diagnosis and pre-treatment of
lung cancer patients in multicultural Australia.
Lung cancer among the CALD population
The LEAD project focuses on these differences, because
there is evidence suggesting that compared to Caucasian
lung cancer patients, CALD patients are a vulnerable group,
with poorer survival rates and a lower likelihood of receiving
timely and appropriate treatment [9–12]. Possible reasons
for these poorer outcomes include more advanced stage at
diagnosis, cultural beliefs towards treatment, fatalism and
medical mistrust [10, 13, 14].
Similar to many Western countries, people from CALD
backgrounds account for a significant proportion of Aus-
tralia’s population. Data from the most recent census
shows that in 2016, Australia’s population consisted of
people from over 300 ethnic groups with more than a
quarter (26%) born overseas and a further one-fifth (20%)
having at least one overseas-born parent [15]. This cul-
tural diversity has been reflected in lung cancer patients.
A recent retrospective cohort study with six public and
two private hospitals in Victoria Australia found that, of
the 1417 patients diagnosed with lung cancer between
2011 and 2014, 51% were born overseas [16].
However, most of current research with the CALD popu-
lation has been conducted in the United States (US). Given
the significant differences in the healthcare system and the
composition of the CALD communities between Australia
and the US (for example, the top three countries of birth
for the overseas-born population in 2016 were England,
New Zealand, and China for Australia [Australian Bureau
of Statistics, 2017], and Mexico, China and India for the US
[Migration Policy Institute, 2018]), it is important to
explore whether the finding of poorer outcomes among
CALD lung cancer patients in the US studies also applies
to the Australian context.
Model of Pathways to Treatment
The diagnostic and treatment pathway of lung cancer pa-
tients is complex, comprising multiple stages from pa-
tients noticing symptoms and seeking help from health
professionals, to obtaining a formal diagnosis and starting
treatment [6]. It is, therefore, useful to apply a theoretical
model in cancer pathway studies to inform the description
and measurement of the stages along this pathway [6].
The Model of Pathways to Treatment [8] will be used in
the LEAD project as the theoretical model to understand
and measure the cancer diagnostic and pre-treatment path-
way. This model is built on the findings from a systematic re-
view and has been incorporated into the Aarhus Statement,
an international guideline for the design and reporting of
studies on early cancer diagnosis [6]. An important feature of
this model is that it uses events that can be readily
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understood by patients, clinicians and researchers to de-
fine the key time intervals underlying this pathway [8]. As
shown in Fig. 1, these intervals are: (1) the appraisal inter-
val (time between first detection or awareness of a symp-
tom to recognising a need to discuss the symptom with a
healthcare professional), (2) the help-seeking interval
(time from recognising the need to discuss their symp-
toms to attending the first consultation with a healthcare
professional); (3) the diagnostic interval (time from first
consultation to a formal cancer diagnosis), and (4) the
pre-treatment interval (time from the formal diagnosis to
initiation of treatment) [8].
Another important feature of this model is that it con-
siders and categorises factors that are likely to have import-
ant impacts on these time intervals. These include: (1)
patient factors (e.g. demographic, co-morbidities, and cul-
tural factors), (2) healthcare provider and system factors
(e.g. access, healthcare policy), and (3) disease factors (e.g.,
site, size) [8]. This framework facilitates a systematic inves-
tigation of the enablers and barriers that are encountered
along the cancer diagnostic and pre-treatment pathway.
Study aims
The two aims of the LEAD project are (1) to explore the
differences in the four time intervals along the lung cancer
diagnostic pathway between CALD and Anglo-Australian
patients, and (2) to explore patient, health care provider,
and health system factors that are associated with the
differences in time intervals between the two groups. Based
on earlier studies, we hypothesise that CALD patients will
report longer time intervals than Anglo-Australian patients.
There is no specific hypothesis associated with the second
research aim because it is exploratory in nature.
Methods/Design
Study design and setting
LEAD is a prospective, observational cohort study using a
mixed-method approach to gather and interpret quantitative
and qualitative data. Quantitative information on time inter-
vals (see Fig. 2) and other factors will be gathered via patient
survey, GP review of general practice records, and case-note
analysis of hospital records. Qualitative information will be
gathered via structured interviews with lung cancer patients,
general practitioners (GPs), and hospital specialists.
The LEAD project will be conducted in five sites
across three states in Australia: three Integrated Cancer
Services in Melbourne, Victoria; one public hospital in
Sydney, New South Wales; and, one public hospital in
Brisbane, Queensland. These health services provide
coverage for all of metropolitan regions of Melbourne,
Sydney and Brisbane and include significant numbers of
lung cancer patients, including CALD patients.
Participants and recruitment
Three groups of participants will be recruited for this
study: lung cancer patients, GPs and hospital specialists.
Fig. 1 Model of Pathways to Treatment [8]. HCP: health care provider
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Lung cancer patients
Lung cancer patients will be involved in both the quantita-
tive and the qualitative components of LEAD. The quanti-
tative component involves a patient survey and a case-note
analysis of hospital records. The qualitative component in-
volves an interview. The patient eligibility criteria are: (1)
have a diagnosis of primary lung cancer at the study sites
within the past month or during the recruitment phase,
and (2) be of CALD or Anglo-Australian descent. We will
use prospective recruitment and also include patients who
have been diagnosed within the past month to minimise
the risk of recall bias and participant attrition due to death
or terminal illness.
Patients of CALD descent are defined in the study as
those who were born overseas and from one of the fol-
lowing ethnic groups: Arabic, Chinese, Greek, Italian,
and Vietnamese. These are the most common ethnic
groups for overseas-born people in Australia [15].
Anglo-Australian patients will be defined as those who
were born in Australia or other major English-speaking
countries (Canada, New Zealand, the United Kingdom,
and the US). Patients who are pregnant or aged under
18 years will be excluded from the study because lung
cancer among these two groups is very uncommon and
those patients tend to have a different diagnostic path-
way to the general population [17, 18].
Eligible patients will be identified through the list of
new cases presented at the respective lung multidisciplin-
ary team meetings. Additional recruitment sources, such
as the bronchoscopy lists, might be used for some study
sites on a local basis. The project coordinators will regu-
larly go through these lists throughout the recruitment
phase or until the required sample size has been reached.
After an eligible patient has been identified, the site
coordinator will send a letter to invite the patient to par-
ticipate in the patient survey and the patient interview.
Patients may consent to take part in either or both activities.
A waiver of consent has been obtained for the case-note
analysis of hospital records, and the required data will be
gathered by a hospital staff member with authorised access
to medical records.
The invitation letter will be sent together with the pa-
tient survey and a reply-paid envelope. Two weeks after
the initial invitation, the patients will receive a reminder
phone call and a reminder letter from the site coordin-
ator. For CALD patients, the invitation letter and the
survey will be provided in English as well as their pre-
ferred languages. As an incentive to take part in the
interview, the patients will be offered a $40 gift card, in
line with the average hourly Australian wage.
GPs
The GP of enrolled lung cancer patients will be invited
to take part in LEAD. Their involvement in the quantita-
tive component will be in the form of a review of their
general practice records, and their involvement in the
qualitative component will be in the form of an inter-
view. The GP will be identified by the patients who have
chosen to participate in the study and who have pro-
vided consent for the research team to access their hos-
pital and general practice medical records (see Fig. 3).
With their patients’ consent, the GPs will be posted a
letter inviting them to complete a review of the patient’s
medical records at the general practice and to take part
in an interview. The letter will be posted together with a
GP review proforma, the patient’s consent form, and a
Fig. 2 Study design of the LEAD. GP: General Practitioner
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reply-paid envelope. A reminder letter will be sent 2
weeks after the initial invitation. To increase GPs’ inter-
est in taking part in the study, a certificate of participa-
tion will be provided to GPs who complete the review.
The GPs will be able to use this certificate to self-report
to relevant medical colleges for Continuing Professional
Development points. As an incentive to take part in the
interview, the GPs will be offered a $200 gift card, In
line with the average hourly consultancy rate for a GP
and for lost earnings during the interview.
Hospital specialists
Hospital specialists at the five study sites providing care to
lung cancer patients will be invited to take part in a quali-
tative interview. Hospital specialists will include thoracic
surgeons, respiratory physicians, medical oncologists,
radiation oncologists, nurses, radiologists, pathologists,
palliative care physicians, social workers, and allied health
professionals. The LEAD coordinators at each site will
send an invitation email to these staff and ask interested
staff to contact the project manager directly. A reminder
email will be sent 2 weeks after the initial invitation. No
financial incentive payment will be provided to the spe-
cialists as the interviews will be conducted during their
normal working hours at the study sites.
Data collection and measures
Patient Survey
The patient survey comprises the Cancer Symptom
Interval Measure (C-SIM) used in previous lung cancer
studies [19, 20]. It includes questions on the timing of
the onset and presentation of symptoms potentially
related to lung cancer, as well as questions about
GP-initiated tests and the patient’s socio-demographic
characteristics (e.g. education, occupation), health status
(e.g. smoking history and co-morbidities), and health
literacy. When completing the survey, the patients will
be able to choose: 1) to complete the survey anonym-
ously, or (2) to provide identifiable personal information
and written consent for the research team to access their
hospital and general practice medical records.
GP review proforma
GP review proforma is based on an earlier one used
by J Emery, F Walter, V Gray, C Sinclair, D Howting,
M Bulsara, C Bulsara, A Webster, K Auret, C Saunders,
et al. [20]. It captures key data on presentations to general
practice and investigations conducted by GPs prior to
referring the patient to a specialist. It will also collect
demographic and health system information of the
GP’s practice.
Case-note analysis tool
Data for the case-note analysis will be collected using an
audit tool with identifiable patient information removed.
This audit tool is based on those previously used by the
research team [21, 22] and will collect data relevant to
lung cancer diagnosis and treatment (e.g. date of diagno-
sis, date of GP referral) and patients’ demographic back-
ground (e.g. gender, age).
Fig. 3 Flow chart of the LEAD project. GP: General Practitioner
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Qualitative interviews
Questions for the interviews with lung cancer patients,
GPs, and hospital specialists will be developed from the
Model of Pathways to Treatment, and cover patient,
health provider, and health system factors that might in-
fluence the diagnostic pathway of lung cancer patients.
For interviews with lung cancer patients, questions will
also be based on the interview schedule used in an earl-
ier study [20]. With participants’ consent, all interviews
will be audio-taped.
Lung cancer patients will be able to choose to have the
interview conducted face-to-face or via telephone. The
interview will be conducted at a time convenient to the
participant and will last approximately 1 hour. For
CALD patients, a qualified interpreter or a bilingual re-
searcher will be involved in the interview as required.
The patient’s carer is welcome to take part in the inter-
view if preferred by the patient. For GPs and hospital
specialists, the interviews will be conducted via tele-
phone at a time convenient to the participant. The inter-
view will last between 30 min to 1 hour.
Ethics, consent and permissions
Our project has received ethics approval for a multiple-site
study from the Monash Health Human Research Ethics
Committee (HREC/16/MonH/311) and research govern-
ance approval from all participating sites. Three forms of
consent will be used in the study: waiver of consent,
implied consent and written consent. Waiver of consent
will be used for the case-note analysis component and im-
plied consent will be used for the patient survey and the
GP review components. Written consent will be obtained
for patients who have provided consent in the survey for
the research team to access their hospital and general prac-
tice medical records. It will also be used for all participants
in the qualitative arm.
Statistical Considerations
Quantitative component
Comparions between CALD and Anglo-Australian pa-
tients on time intervals will be performed using the log-
rank test. Cox proportional hazards regression will be
used to estimate the relative effect of factors (e.g. patient
factors, healthcare provider factors, health systems factors)
on the underlying hazard rate governing time intervals.
Independent groups will be compared using t-tests for
continuous variables and chi-square tests for categorical
variables. Linear modelling methods for continuous and
categorical data may also be used to undertake compari-
sons adjusted for selected covariates.
A Danish cohort study demonstrated that 60 days was
a clinically significant diagnostic interval beyond which
mortality increased [23] while another study reported
that the median tumour volume doubling time of all
lung cancers is 98 days (IQR 108 days) [24]. Based on
these data, a 20% increase in tumour size every 28 days
appears plausible and capable of affecting disease staging.
A between-group difference in the time to treatment of
28 days or more would therefore be clinically significant.
A total of 290 participants (145 per group) will provide
90% power with a two-sided alpha of 0.05 to detect an
absolute difference of 28 days in median time to diagnosis
(60 days versus 88) based on a log-rank test. We anticipate
that 724 patients (362 per group) will need to be con-
tacted in order to obtain a sample of this size assuming a
50% patient survey completion rate (based on previous
studies, e.g., Emery et al., 2013; Walter et al., 2015), and a
80% GP review completion rate.
Qualitative component
Based on our experience, data saturation is likely to be
reached with the following interview sample sizes: 60
lung cancer patients (10 patients per language group),
20 GPs, and 20 specialists.
All interviews will be audio-taped, and transcription,
translation, coding, and analysis will occur concurrently
with data collection. Thematic analysis will be conducted
using a constant comparative method to identify similar-
ities and differences in the content [25]. Data will be
analysed inductively and deductively. The interviews will
then be incorporated into NVivo version 10 for more
structured coding and analysis.
Discussion
The LEAD project is the first Australian study to com-
pare the time intervals along the lung cancer diagnostic
pathway between CALD and Anglo-Australian patients.
The project will also explore the underlying patient,
healthcare provider, and health system factors that influ-
ence the time intervals in the two groups. This informa-
tion will improve our understanding of the effect of
cultural diversity on health outcomes among lung cancer
patients and will inform future interventions aimed at
early diagnosis and treatment for lung cancer, particu-
larly patients from CALD backgrounds.
There are a number of strengths in the design of the
LEAD study that could be considered in future studies.
Firstly, the Model of Pathways to Treatment (Walter
et al., 2012) will be used to conceptualise and measure
the various stages along the cancer diagnostic pathway.
This model provides clear definitions and measurements
of time intervals along the cancer diagnostic pathway
and has been incorporated into the Aarhus Statement,
an international guideline for the design and reporting
of studies on early cancer diagnosis [6]. The adoption of
such a model enables a systematic approach in data col-
lection and allows data comparison between studies and
across cancer types.
Mazza et al. BMC Cancer  (2018) 18:754 Page 6 of 8
Secondly, the study will use both quantitative and qualita-
tive methods and will collect information from multiple
groups, including lung cancer patients, GPs and specialists.
The inclusion of these different methods and participant
groups is particularly important given the complexity of the
cancer diagnostic and pre-treatment pathway. Compared to
earlier studies where a single research method or partici-
pant group was used [e.g. 10, 13], such an approach enables
a more comprehensive picture of the diagnostic pathway.
Thirdly, the study includes both CALD and
Anglo-Australian patients. As noted in a systematic re-
view of cancer beliefs in CALD populations, one limita-
tion of current studies in this area is that few have
comparator groups of the local population, making it
difficult to disentangle local- versus ethnicity-specific
factors in these studies [14]. Compared to these studies,
the inclusion of both groups in our study enables a dir-
ect comparison between the two groups, leading to a
deeper understanding of cultural differences in the diag-
nostic pathways.
In conclusion, the LEAD project will be the first Austra-
lian study to provide comprehensive data on the lung can-
cer diagnostic pathway for CALD and Anglo-Australian
patients. Guided by the Model of Pathways to Treatment,
this mixed-method, observational cohort study will in-
form the development of interventions aimed at im-
proving the diagnosis and treatment of lung cancer in
multicultural countries.
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